In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Akili brings in $55mm Series C round to advance digital medicine pipeline; later adds on $13mm

Executive Summary

Akili Interactive Labs Inc. (cognitive dysfunction-focused prescription digital medicines) raised $55mm in a Series C round led by Temasek. Other participants included Baillie Gifford, Amgen Ventures, M Ventures (Merck KGAA's CVC fund), Jazz Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies. The company will use the proceeds to advance through regulatory and commercial launch its lead compound AKLT01, a tablet-based game for pediatric attention deficit hyperactivity disorder (ADHD), for which the company completed a pivotal trial and plans to file for approval with the FDA under the 510(k) pathway in the coming months. Akili will also apply some of the funds to progress its other candidates for depression (AKLT03 and AKLT04) and multiple sclerosis (AKLT05) into registration trials and for expansion of its pipeline.
Deal Industry
  • Digital Health
  • Medical Devices
  • Pharmaceuticals
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Monitoring Equipment & Devices
    • Rehabilitation Equipment and Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies